Stockreport

Roche Is The 'Value Play' Of The 2026 Obesity Gold Rush [Seeking Alpha]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF CT388-103's Phase 2 obesity data show placebo-adjusted weight loss up to 22.5% at 48 weeks, supporting blockbuster potential and competitive positioning. DCF sensitiv [Read more]